Overexpression levels of cripto‑1 predict poor prognosis in patients with prostate cancer following radical prostatectomy

  • Authors:
    • Yan Liu
    • Jianan Wang
    • Tong Yang
    • Ranlu Liu
    • Yong Xu
  • View Affiliations

  • Published online on: July 4, 2019     https://doi.org/10.3892/ol.2019.10555
  • Pages: 2584-2591
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overexpression of cripto‑1 (CR‑1), an epidermal growth factor‑cripto‑1/FRL‑1/Cryptic family protein, has been reported in multiple types of malignancy. However, the clinical functions of CR‑1 in prostate cancer (PCa) remain largely unclear. The objective of the present study was to investigate the association between CR‑1 expression and the clinicopathological features and prognosis of PCa. CR‑1 expression was evaluated in 138 PCa tissues and 67 benign prostate hyperplasia (BPH) tissues using immunohistochemistry. The association between the clinicopathological features of patients with PCa and CR‑1 expression was analyzed using a χ2 test. Receiver operating characteristic (ROC) curve and Cox regression model were used to analyze the association between CR‑1 expression and biochemical recurrence (BCR)‑free survival. It was revealed that the protein expression of CR‑1 was markedly higher in PCa tissues than in BPH tissues. The mRNA expression of CR‑1 in PCa tissue and cells was also significantly higher than in BPH tissue and the normal RWPE‑1 prostate cell line (P<0.05). In addition, high CR‑1 expression was significantly associated with prostate‑specific antigen level (P=0.008), Gleason score (P=0.011) and lymph node metastasis (P=0.025) in patients with PCa. ROC curve indicated that patients with elevated expression of CR‑1 exhibited shorter BCR‑free survival (P<0.001). Furthermore, multivariate statistical analysis demonstrated that overexpression of CR‑1 may be a novel predictor for prognosis of patients with PCa. Accordingly, the present study considered CR‑1 to be a valuable predictor of poor prognosis and progression in PCa, and a potential therapeutic target for patients with PCa.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Y., Wang, J., Yang, T., Liu, R., & Xu, Y. (2019). Overexpression levels of cripto‑1 predict poor prognosis in patients with prostate cancer following radical prostatectomy. Oncology Letters, 18, 2584-2591. https://doi.org/10.3892/ol.2019.10555
MLA
Liu, Y., Wang, J., Yang, T., Liu, R., Xu, Y."Overexpression levels of cripto‑1 predict poor prognosis in patients with prostate cancer following radical prostatectomy". Oncology Letters 18.3 (2019): 2584-2591.
Chicago
Liu, Y., Wang, J., Yang, T., Liu, R., Xu, Y."Overexpression levels of cripto‑1 predict poor prognosis in patients with prostate cancer following radical prostatectomy". Oncology Letters 18, no. 3 (2019): 2584-2591. https://doi.org/10.3892/ol.2019.10555